Urs Spitz (left) – CEO and President, Biosynth Carbosynth and Philip Noone (right) – CEO, Aalto Bio Reagents
Dublin, 25 May 2022 - Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease is delighted to announce its acquisition today by Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry.
The acquisition is a further milestone in both Aalto and Biosynth’s development. Aalto’s well established and trusted brand of products, including an extensive range of proteins, antigens, antibodies, disease state human plasma and biospecimens, will be combined with Biosynth’s expertise in enzyme substrates, carbohydrate, nucleoside chemistry and custom peptide synthesis, broadening their capabilities and offerings to the IVD and life science industries.
Philip Noone, CEO of Aalto said “We are thrilled to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto’s industry leading products and key focus on emerging disease are an excellent fit with Biosynth’s products. We see huge opportunities for our combined companies to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future.”
Dr. Urs Spitz, CEO and President of Biosynth, added, “This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries. It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and its employees and look forward to working with them to continue to grow our offering to the diagnostics industry.”
About Aalto Bio Reagents
Aalto Bio Reagents, founded in 1978, is a leading developer and provider of biological raw materials to the in-vitro diagnostics industry and to research laboratories globally. It serves the largest multinational companies in the industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base. For further information please visit www.aaltobioreagents.com
About Biosynth Carbosynth
Biosynth Carbosynth is a supplier of critical materials to the life science industry with global research, manufacturing and distribution facilities. It is the supplier of choice for many in the pharmaceutical and diagnostic sectors and manufactures and sources a vast range of chemical and biochemical products. The company specializes in carbohydrates, nucleosides, enzyme substrates, peptides, phospholipids, antimicrobials, APIs and natural products and has a full range of reagents for protein production and analysis. Headquartered in Staad, Switzerland, Biosynth Carbosynth is owned by KKR, Ampersand Capital Partners and management. Find out more about Biosynth Carbosynth at www.biosynth-carbosynth.com.